Monte Rosa Therapeutics Inc
GLUE6.930USD
+0.570+8.96%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
427.70MMarket Cap
17.70P/E TTM
More Details of Monte Rosa Therapeutics Inc Company
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Company Info
Ticker SymbolGLUE
Company nameMonte Rosa Therapeutics Inc
IPO dateJun 24, 2021
CEODr. Markus Warmuth, M.D.
Number of employees134
Security typeOrdinary Share
Fiscal year-endJun 24
Address321 Harrison Avenue
CityBOSTON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02118
Phone16179492643
Websitehttps://www.monterosatx.com/
Ticker SymbolGLUE
IPO dateJun 24, 2021
CEODr. Markus Warmuth, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Sharon Townson, Ph.D.
Dr. Sharon Townson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
36.00K
--
Ms. Jennifer Champoux
Ms. Jennifer Champoux
Chief Operating Officer
Chief Operating Officer
30.00K
--
Dr. Filip Janku, M.D., Ph.D.
Dr. Filip Janku, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
9.19K
-74.47%
Dr. Philip Nickson, J.D., Ph.D.
Dr. Philip Nickson, J.D., Ph.D.
Chief Business and Legal Officer
Chief Business and Legal Officer
--
-100.00%
Dr. Kimberly L. Blackwell, M.D.
Dr. Kimberly L. Blackwell, M.D.
Independent Director
Independent Director
--
--
Dr. Markus Warmuth, M.D.
Dr. Markus Warmuth, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Anthony M. Manning, Ph.D.
Dr. Anthony M. Manning, Ph.D.
Independent Director
Independent Director
--
--
Ms. Christine Siu
Ms. Christine Siu
Independent Director
Independent Director
--
--
Dr. Chandra P. Leo, M.D.
Dr. Chandra P. Leo, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Sharon Townson, Ph.D.
Dr. Sharon Townson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
36.00K
--
Ms. Jennifer Champoux
Ms. Jennifer Champoux
Chief Operating Officer
Chief Operating Officer
30.00K
--
Dr. Filip Janku, M.D., Ph.D.
Dr. Filip Janku, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
9.19K
-74.47%
Dr. Philip Nickson, J.D., Ph.D.
Dr. Philip Nickson, J.D., Ph.D.
Chief Business and Legal Officer
Chief Business and Legal Officer
--
-100.00%
Dr. Kimberly L. Blackwell, M.D.
Dr. Kimberly L. Blackwell, M.D.
Independent Director
Independent Director
--
--
Dr. Markus Warmuth, M.D.
Dr. Markus Warmuth, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 23
Updated: Sat, Aug 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
12.46%
T. Rowe Price Associates, Inc.
10.09%
BVF Partners L.P.
9.16%
Versant Ventures
9.15%
Baker Bros. Advisors LP
7.96%
Other
51.17%
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
12.46%
T. Rowe Price Associates, Inc.
10.09%
BVF Partners L.P.
9.16%
Versant Ventures
9.15%
Baker Bros. Advisors LP
7.96%
Other
51.17%
Shareholder Types
Shareholders
Proportion
Investment Advisor
29.74%
Hedge Fund
25.48%
Venture Capital
24.07%
Investment Advisor/Hedge Fund
19.03%
Research Firm
1.76%
Individual Investor
0.85%
Family Office
0.12%
Bank and Trust
0.11%
Pension Fund
0.07%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
232
62.74M
101.99%
-2.45M
2025Q1
235
60.82M
98.88%
-7.09M
2024Q4
220
61.73M
100.63%
-766.83K
2024Q3
200
57.64M
94.07%
-4.29M
2024Q2
191
55.42M
93.92%
+8.23M
2024Q1
185
49.41M
98.58%
+2.43M
2023Q4
187
49.83M
99.64%
+961.54K
2023Q3
187
51.89M
104.49%
+4.85M
2023Q2
202
40.69M
82.04%
-4.78M
2023Q1
192
47.34M
97.38%
+2.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
New Enterprise Associates (NEA)
7.69M
12.51%
--
--
Mar 31, 2025
T. Rowe Price Associates, Inc.
6.56M
10.66%
-475.63K
-6.76%
Mar 31, 2025
BVF Partners L.P.
5.66M
9.2%
+1.27M
+28.84%
Mar 31, 2025
Versant Ventures
5.65M
9.19%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
4.92M
7.99%
--
--
Mar 31, 2025
Avoro Capital Advisors LLC
4.65M
7.55%
+300.55K
+6.92%
Mar 31, 2025
Suvretta Capital Management, LLC
3.36M
5.46%
+1.80M
+114.86%
Apr 09, 2025
BlackRock Institutional Trust Company, N.A.
3.22M
5.24%
-73.74K
-2.24%
Mar 31, 2025
The Vanguard Group, Inc.
3.10M
5.04%
-56.32K
-1.78%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
Fidelity Nasdaq Composite Index ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Health Innovation Active ETF
0%
SPDR S&P Biotech ETF
0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
SPDR Portfolio MSCI Global Stock Market ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
iShares Health Innovation Active ETF
Proportion0%
SPDR S&P Biotech ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
